Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now directly owns 8,920 shares of […]

BNP Paribas lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 4.9% in the third quarter, Holdings Channel reports. The fund owned 77,395 shares of the biopharmaceutical company’s stock after selling 4,020 shares during the period. BNP Paribas’ holdings in Gilead Sciences were worth $6,488,000 as of its most recent SEC filing. […]

Kiltearn Partners LLP acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 3rd quarter, Holdings Channel.com reports. The institutional investor acquired 72,600 shares of the biopharmaceutical company’s stock, valued at approximately $6,087,000. Other institutional investors also recently bought and sold shares of the company. FMR LLC grew its […]